Big Names Join Clinical Proteomics Push in 2011, Offering Ray of Optimism Amidst Difficult Year | GenomeWeb

By Adam Bonislawski

Proteomics in 2011 continued its long, hard slog toward the clinic, battling now-familiar challenges like sluggish test sales, unproven platforms, and the vagaries of the regulatory process.

But while clinical proteomics efforts in the past have often been pushed by smallish start-ups, 2011 saw investments in the space from heavy-hitters including Agilent, Myriad Genetics, and Thermo Fisher Scientific.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.